|
|
|
||
(State or other jurisdiction of
incorporation or organization)
|
(Commission File Number)
|
(I.R.S. Employer
Identification No.)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of Each Class
|
Trading Symbol
|
Name of Exchange on Which
Registered
|
||
|
|
|
Item 8.01 |
Other Events.
|
Item 9.01 |
Financial Statements and Exhibits.
|
Exhibit
No.
|
Document
|
|
Press Release, dated September 27, 2023
|
||
104
|
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL
|
OCUPHIRE PHARMA, INC.
|
||
Date: September 27, 2023
|
By:
|
/s/ Richard J. Rodgers
|
Richard J. Rodgers
|
||
Interim President and Chief Executive Officer
|